HC Wainwright Issues Pessimistic Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target lowered by analysts at HC Wainwright from $110.00 to $100.00 in a research note issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright’s price objective indicates a potential upside of 14.05% from the company’s previous close.

RYTM has been the subject of a number of other reports. Citigroup lowered their price objective on shares of Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating for the company in a research note on Tuesday. TD Cowen restated a “buy” rating on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Morgan Stanley lowered their price target on shares of Rhythm Pharmaceuticals from $150.00 to $136.00 and set an “overweight” rating for the company in a research report on Tuesday. Jefferies Financial Group reiterated a “buy” rating and set a $125.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Tuesday, March 3rd. Finally, Stifel Nicolaus set a $131.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Rhythm Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $131.13.

Rhythm Pharmaceuticals Stock Performance

Rhythm Pharmaceuticals stock opened at $87.68 on Wednesday. The company has a 50 day moving average price of $99.77 and a 200-day moving average price of $102.81. Rhythm Pharmaceuticals has a fifty-two week low of $45.90 and a fifty-two week high of $122.20. The company has a market capitalization of $5.99 billion, a PE ratio of -28.19 and a beta of 2.06.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company had revenue of $57.25 million for the quarter, compared to analysts’ expectations of $56.16 million. During the same quarter in the prior year, the firm earned ($0.72) earnings per share. Rhythm Pharmaceuticals’s revenue was up 36.9% compared to the same quarter last year. On average, analysts forecast that Rhythm Pharmaceuticals will post -4.32 earnings per share for the current year.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $89.56, for a total transaction of $502,789.84. Following the sale, the chief accounting officer directly owned 160 shares in the company, valued at $14,329.60. This trade represents a 97.23% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Hunter C. Smith sold 4,385 shares of Rhythm Pharmaceuticals stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the transaction, the chief financial officer owned 110,512 shares of the company’s stock, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 27,267 shares of company stock worth $2,719,955. 6.10% of the stock is owned by company insiders.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC grew its position in shares of Rhythm Pharmaceuticals by 303.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock valued at $28,000 after purchasing an additional 200 shares during the period. Smartleaf Asset Management LLC lifted its position in shares of Rhythm Pharmaceuticals by 97.2% in the third quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock valued at $29,000 after acquiring an additional 141 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Rhythm Pharmaceuticals by 1,110.3% in the third quarter. Farther Finance Advisors LLC now owns 351 shares of the company’s stock worth $35,000 after acquiring an additional 322 shares during the last quarter. Optiver Holding B.V. boosted its stake in shares of Rhythm Pharmaceuticals by 65.2% in the third quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after acquiring an additional 144 shares during the last quarter. Finally, SBI Securities Co. Ltd. increased its position in shares of Rhythm Pharmaceuticals by 73.2% during the fourth quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after purchasing an additional 145 shares in the last quarter.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Rhythm reported strong FY25 revenue growth and previously beat Q4 expectations, which underpinned optimism around broader demand for IMCIVREE and a separate PDUFA filing for acquired hypothalamic obesity. This supports a longer-term commercial story even after the EMANATE miss. Q4 Beat & PDUFA
• Positive Sentiment: Several major banks lowered price targets but maintained bullish ratings (Citigroup, RBC, BofA, Morgan Stanley, Needham, Citizens JMP). Analysts trimmed PTs (e.g., Citi $136→$131, RBC $140→$130) but retained buy/outperform views, indicating they still see substantial upside from current levels. Analyst Price Target Moves
• Neutral Sentiment: Company release: topline EMANATE statement notes four substudies missed pre-specified primary endpoints, but post‑hoc analyses found statistically significant BMI reductions at 52 weeks in patients with heterozygous variants of POMC/PCSK1 and SRC1 (NCOA1) — a subgroup signal that may inform future regulatory or commercial strategy, but is not a primary endpoint win. Company Topline Release
• Neutral Sentiment: Investor/transcript coverage highlights management’s commentary and post‑hoc analyses from the Phase 3 EMANATE transcript; these provide detail but do not change the fact primary endpoints were missed — markets treat transcript detail as informational rather than corrective. EMANATE Transcript
• Negative Sentiment: Late‑stage failure: multiple media reports and Reuters coverage confirm IMCIVREE did not meet the main goal in the late‑stage EMANATE trial, which directly clouds the drug’s label expansion prospects and near‑term revenue trajectory tied to these indications. Reuters: Trial Miss
• Negative Sentiment: Coverage emphasizing the clinical setback led to sharp selling pressure and headlines noting shares fell after the announcement; media pieces and sector writeups flag increased short‑term uncertainty around approval expansion and growth assumptions. BioSpace: Trial Failure
• Negative Sentiment: Several consumer/health outlets summarized the miss as a key negative development, noting the market’s reaction; these pieces amplify downside sentiment for near‑term share performance. MSN: Shares Fall

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.